EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel

Francesco Mattana, Erica Palesandro, Valentino Dragonetti, Giuseppe Curigliano, Marcello Tucci, Francesco Ceci

Cancer Treatment Reviews · 2026-11 · 150 · 103216

DOI: 10.1016/j.ctrv.2026.103216 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026-11. Verfasst von Francesco Mattana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Taxoids, Prostatic Neoplasms, Castration-Resistant, Dipeptides, Heterocyclic Compounds, 1-Ring. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TaxoidsProstatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingRadiopharmaceuticalsHumansMaleDocetaxelLutetiumAntineoplastic AgentsProstate-Specific Antigen

Stichwörter der Autor:innen

ChemotherapyPSMAPSMA-RLTProstate CancerRDCsradio-drug conjugatesradioligand therapysequencing

Substanzen

TaxoidscabazitaxelDipeptidesDocetaxelHeterocyclic Compounds, 1-RingLutetiumPSMA-617RadiopharmaceuticalsAntineoplastic AgentsProstate-Specific Antigen

Autor:innen und Institutionen

  • Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Medical Oncology Unit, Edoardo Agnelli Hospital, Pinerolo, Italy.
  • Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy. Electronic address: valentino.dragonetti@ieo.it.
  • Department of Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy.
  • Chief of Medical Oncology, Cardinal Massaia Hospital, Asti, Italy.
  • Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy.

Zitieren

APA

Mattana, F., Palesandro, E., Dragonetti, V., Curigliano, G., Tucci, M., & Ceci, F. (2026). Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel. Cancer Treatment Reviews, 150, 103216. https://doi.org/10.1016/j.ctrv.2026.103216

Vancouver

Mattana F, Palesandro E, Dragonetti V, Curigliano G, Tucci M, Ceci F. Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel. Cancer Treatment Reviews. 2026;150:103216. doi:10.1016/j.ctrv.2026.103216

BibTeX
@article{Mattana2026,
  author = {Mattana, Francesco and Palesandro, Erica and Dragonetti, Valentino and Curigliano, Giuseppe and Tucci, Marcello and Ceci, Francesco},
  title = {Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel},
  journal = {Cancer Treatment Reviews},
  year = {2026},
  volume = {150},
  pages = {103216},
  doi = {10.1016/j.ctrv.2026.103216}
}
Kostenlos starten →